Examining the link between skinfold thickness and survival in certain cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between triceps skinfold thickness and overall survival rates in patients diagnosed with pancreatic cancer, cholangiocarcinoma, and gallbladder cancer. The study aims to address the issue of cachexia, which is common in pancreatic cancer and negatively impacts survival and quality of life. By measuring skinfold thickness, the researchers hope to provide a more accurate assessment of body composition compared to traditional BMI measurements. The findings could help improve treatment strategies and patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed pancreatic, bile duct or gallbladder cancer patients, undergoing therapeutic management (including surgery, chemotherapy or palliative care).
* Age above 18 years old

Exclusion Criteria:

* Other malignant disease
* Underlying intestinal disease that cause absorprtion disorder
* Underlying psychiatric disorder such as eating disorder (bulimia, anorexia)

Where it's running

• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Jong-In Chnag, M.D.
• Email: ji.chang@samsung.com
• Phone: 82-2-3410-3409

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Treatment using CEA-targeted CAR-T cells for advanced solid tumors

  This study is testing a new type of immune therapy using CAR-T cells to see if it can help people with advanced solid tumors that have a specific marker called CEA.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhu, Anhui · NCT06126406

• Finding new biomarkers for biliary tract cancer and gallbladder cancer

  This study is trying to find new markers in blood and tissue samples from patients with biliary tract and gallbladder cancer to help doctors diagnose the disease earlier and predict how well treatments will work.

  Recruiting Herlev and Gentofte Hospital · Herlev, Copenhagen · NCT05184400

• Using virtual reality to help manage pain in GI cancer patients

  This study is testing if virtual reality can help people with GI cancer manage their severe abdominal pain better than standard treatments.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT04907643

• Collecting tumor tissue samples from patients undergoing surgery or biopsy for cancer

  This study is collecting tissue samples from cancer patients having surgery or biopsies to see if they can find new ways to treat different types of cancer.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01915225

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.